The Study
Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study.
This study is like a fair test where half the girls got a new medicine and half got a sugar pill, and nobody knew who got what. It found that the medicine helped girls lose weight and lower bad hormones. But it doesn't prove it will work for everyone or for a long time.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested a drug called liraglutide, usually used for diabetes and weight loss, in women with PCOS who are overweight. It gave one group the drug and another group a dummy pill, then saw what happened after 8 months.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 574 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — losing 5%+ weight improves PCOS symptoms like irregular periods and acne, and lowering male hormones helps with fertility and skin issues.
- 2This drug helped more women reach these goals than a placebo.
- 3Women on liraglutide lost 5.7% of their body weight (vs.
- 41.4% on placebo), 57% lost at least 5% weight (vs.
- 522% on placebo), and their male hormone levels dropped by 28% — even after accounting for weight loss.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Fertility and sterility
Year
2022
Authors
K. Elkind-Hirsch, N. Chappell, Donna Shaler, J. Storment, D. Bellanger
Related Content
Claims (6)
Liraglutide lowers blood glucose levels after fasting and after meals in people with obesity and prediabetes by activating GLP-1 receptors, and this effect does not occur with weight loss, DPP-4 inhibition, or increased natural incretin levels.
In obese women with polycystic ovary syndrome, taking liraglutide 3 mg daily for 32 weeks lowers the free androgen index by 28% compared to placebo, showing a direct reduction in androgen levels not caused by weight loss.
In obese women with polycystic ovary syndrome, taking 3 mg of liraglutide daily for 32 weeks results in a 5.7% average weight loss, compared to 1.4% with a placebo, and reduces fat mass and visceral adipose tissue.
In obese women with polycystic ovary syndrome, taking liraglutide 3 mg daily for 32 weeks results in 56.8% achieving at least 5% weight loss, while 21.7% achieve this with a placebo.
In obese women with polycystic ovary syndrome, taking 3 mg of liraglutide daily for 32 weeks reduces fasting blood glucose and HOMA-IR levels without requiring weight loss.
In obese women with polycystic ovary syndrome, taking 3 mg of liraglutide daily for 32 weeks reduces fat around internal organs and fat in the liver, which is associated with better metabolic function and lower cardiovascular risk.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.